Nurix Therapeutics Inc (NRIX) Unusual Options Activity Today

Checking NRIX unusual options activity helps you spot when traders are making outsized bets on Nurix Therapeutics Inc before the broader market catches on. Nurix Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor NRIX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching NRIX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking NRIX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and NRIX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Catalysts rarely arrive without a footprint, and NRIX unusual options activity is often where that footprint shows up first. Our scanner tracks Nurix Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at NRIX unusual options volume on the call side or chasing put sweeps, Nurix Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.